FDA determined on December 19, 2024 that the tirzepatide injection shortage was resolved, and on February 21, 2025 that the semaglutide injection shortage was resolved
Can pregnant or breastfeeding women use this medicine
This study aimed to elucidate the expression changes of Bax and Bcl-2 and their association with pregnancy-related complications, providing new insights into placental dysfunction during pregnancy and offering a theoretical foundation for clinical diagnosis and prevention
CagriSema Clinical Trials Evidence CagriSema's evidence base is unusually strong for a peptide research stack: two large Phase 3 trials with NEJM publications, plus Phase 1b/2 supporting data
Acetylcysteine after HgCl 2 has also produced conflicting results, with 1) no effect on mercury organ content [Citation27], or 2) reduced kidney and liver mercury content along with restoration of organ function [Citation23, Citation28]
Another issue pertaining to pure and high-quality intravenous glutathione solution is the extremely high cost